Why Can't Medical Device Overseas Registration Costs Be Quoted as a Fixed Price?

Why Can't Medical Device Overseas Registration Costs Be Quoted as a Fixed Price?

Publication date: 2026-07-08 09:00  |  Last updated: 2026-07-08 09:00

Answer: Medical device overseas registration costs cannot be determined on the basis of a single fixed price, because the total cost is driven by the target country, the product risk class, official authority fees, testing and certification requirements, the appointment of a local authorised representative, translation and notarisation, dossier remediation, supplementary clinical evidence, certificate maintenance and the number of deficiency or correction rounds. The workload for a low-risk consumable and for a medium- or high-risk active device is fundamentally different, and the same product will face different documentation requirements in different countries. A professional assessment should therefore calculate official costs, third-party costs, service costs and ongoing maintenance costs separately, so that applicants do not see only the submission fee and underestimate the total investment.

This article has been prepared by the AIMEILI Regulatory Editorial Team based on public regulatory materials, registration practice and the AIMEILI medical device international registration knowledge base.

It addresses the questions that companies should assess first in real international registration, documentation preparation, compliance pathway and post-market maintenance projects.

Key Summary

Medical device overseas registration costs cannot be judged by a fixed price alone. Cost is influenced by the target country, product risk class, official fees, testing and certification, local authorised representation, translation and notarisation, dossier remediation, supplementary clinical evidence, certificate maintenance and the number of deficiency rounds. The workload for a low-risk consumable is entirely different from that for a medium- or high-risk active device, and the same product is subject to different documentation requirements in different countries. A professional assessment should break the budget down into official costs, third-party costs, service costs and subsequent maintenance costs, rather than looking only at the submission fee and underestimating the overall commitment.

Assessment Logic

Companies should first assess the target market, the registration pathway, the commercial launch plan and the current status of the technical documentation together in a single structured overview. If the pathway assessment is not completed first, the project is likely to encounter repeated rework in relation to the local authorised representative, labelling, testing, clinical evidence or certificate maintenance.

Documentation Priorities

Cost and timeline estimates should be broken down into official fees, third-party testing or certification fees, local authorised representative fees, translation and notarisation fees, dossier remediation costs and ongoing maintenance costs. Looking only at the submission fee or the official review timeline will generally not reflect the true level of project investment.

Common Misconceptions

A frequent misconception is to treat the local authorised representative as an ordinary commercial contact, while overlooking its responsibilities for receiving regulatory communications, maintaining the certificate, supporting adverse event handling and transferring documentation. If the representative arrangement is unclear, it may later affect the ability to change distributors and to retain market control.

AIMEILI Perspective

AIMEILI recommends that companies assess this question as part of project initiation rather than addressing it on an ad hoc basis shortly before submission. A more reliable approach is to first complete the product classification, documentation gap analysis, priority ranking of target countries, identification of the local responsible entity and post-market maintenance arrangements, and then build an executable registration plan.

Further Reading

• Can a registration be submitted when the technical file is incomplete?
• What factors generally determine the registration timeline?
• How do UDI and product classification codes affect overseas registration?
• How should medical device companies select their first batch of target countries for international expansion?
• What maintenance obligations remain after obtaining an overseas medical device registration certificate?
• How is a technical file gap assessment carried out for overseas medical device registration?
• What technical documentation requirements apply under the EU MDR for medical devices?
• What procedures are required to export Chinese medical devices to Indonesia?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supplementary references.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.